US Pharma MarketingCould engaging the immune system improve AML outcomes?
By Ivan Diaz-Padilla, Senior Vice President and Global Head, Oncology Therapeutic Area Unit, R&D at Ipsen With unmet need still high in AML, new approaches are exploring whether engaging immune responses could help improve long-term disease control.
With unmet need still high in AML, new approaches are exploring whether engaging immune responses could help improve long-term disease control.
Source: FierceBiotech